Atara Biotherapeutics, Inc. (ATRA): who owns it and who trades it
As of Nov 16, 2026, ATRA insiders reported 18 open-market sales worth $3.9M and 2 purchases worth $5.7M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Panacea Innovation Ltd (10% owner), with $3.2M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Atara Biotherapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ATRA
35 funds and institutions reported ATRA shares worth $51.3M at the end of Q2 2026, about 55% of the company. The largest holder is EcoR1 Capital, LLC with 19.0%.
Funds and institutions (13F) 55%Everyone else 45%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 1.55M | 18.98% | $17.8M | +1458% |
| Adage Capital Partners Gp, L.l.c. | 850,000 | 10.39% | $9.8M | +21% |
| Point72 Asset Management, L.P. | 687,718 | 8.41% | $7.9M | +254% |
| Redmile Group, LLC | 441,701 | 5.40% | $5.1M | No change |
| Vanguard Capital Management LLC | 247,047 | 3.02% | $2.8M | +13% |
| Mackenzie Financial Corp | 233,249 | 2.85% | $2.7M | -26% |
| BlackRock, Inc. | 84,455 | 1.03% | $970K | +7% |
| Geode Capital Management, LLC | 75,128 | 0.92% | $863K | +14% |
| Staley Capital Advisers Inc | 50,000 | 0.61% | $574K | No change |
| Vanguard Fiduciary Trust Co | 43,036 | 0.53% | $494K | +28% |
| Acadian Asset Management LLC | 38,845 | 0.47% | $444K | -70% |
| Jane Street Group, LLC | 30,345 | 0.37% | $348K | -10% |
| State Street Corp | 26,453 | 0.32% | $304K | No change |
| Northern Trust Corp | 16,591 | 0.20% | $190K | +34% |
| FMR LLC (Fidelity) | 16,238 | 0.20% | $186K | No change |
| XTX Topco Ltd | 15,303 | 0.19% | $176K | New |
| Bridgeway Capital Management, LLC | 14,000 | 0.17% | $161K | -57% |
| Millennium Management LLC | 12,680 | 0.16% | $146K | -73% |
| Citadel Advisors LLC | 10,159 | 0.12% | $117K | New |
| Morgan Stanley | 9,178 | 0.11% | $105K | +0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ATRA insiders reported $5.7M of open-market purchases and $3.9M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Brian N Cherry | Director | Purchase | 104,166 | $9.60 | $1000K | Form 4 |
| Aug 17, 2026 | AnhCo Nguyen | CEO | Sale | 5,062 | $8.08 | $40.9K | Form 4 |
| May 18, 2026 | AnhCo Nguyen | CEO | Sale | 5,241 | $9.13 | $47.9K | Form 4 |
| May 18, 2026 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 2,414 | $9.13 | $22K | Form 4 |
| May 7, 2026 | Panacea Innovation Ltd +1 | 10% owner | Sale | 313,446 | $10.10 | $3.2M | Form 4 |
| May 7, 2026 | EcoR1 Capital, LLC | 10% owner | Purchase | 507,407 | $9.35 | $4.7M | Form 4 |
| Mar 2, 2026 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 377 | $5.08 | $1.9K | Form 4 |
| Mar 2, 2026 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 1,603 | $5.08 | $8.1K | Form 4 |
| Mar 2, 2026 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 24 | $5.08 | $122 | Form 4 |
| Mar 2, 2026 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 100 | $5.08 | $508 | Form 4 |
| Mar 2, 2026 | AnhCo Nguyen | CEO | Sale | 58 | $5.08 | $295 | Form 4 |
| Mar 2, 2026 | AnhCo Nguyen | CEO | Sale | 1,298 | $5.09 | $6.6K | Form 4 |
| Mar 2, 2026 | AnhCo Nguyen | CEO | Sale | 198 | $5.08 | $1K | Form 4 |
| Mar 2, 2026 | AnhCo Nguyen | CEO | Sale | 1,442 | $5.09 | $7.3K | Form 4 |
| Jan 12, 2026 | James Huang +1 | Director | Sale | 80,554 | $6.07 | $489K | Form 4 |
| Nov 17, 2025 | AnhCo Nguyen | CEO | Sale | 56 | $13.19 | $739 | Form 4 |
| Nov 17, 2025 | AnhCo Nguyen | CEO | Sale | 2,859 | $13.19 | $37.7K | Form 4 |
| Nov 17, 2025 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 1,645 | $13.19 | $21.7K | Form 4 |
| Nov 17, 2025 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 74 | $13.19 | $976 | Form 4 |
| Nov 17, 2025 | Yanina Grant-Huerta | Chief Accounting Officer | Sale | 85 | $13.19 | $1.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% owner | $4.7M | – | May 7, 2026 |
| Panacea Innovation Ltd | 10% owner | – | $3.2M | May 7, 2026 |
| Brian N Cherry | Director | $1000K | – | Sep 4, 2026 |
| James Huang | Director, 10% owner | – | $489K | Jan 12, 2026 |
| AnhCo Nguyen | President and CEO, Director | – | $142K | Aug 17, 2026 |
| Yanina Grant-Huerta | Chief Accounting Officer | – | $56.5K | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ATRA short interest
Low short interest. 3.0% of ATRA shares are sold short: about 1 share in 34. Over the last 12 reports the number of shares short went down 46%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 296,651 ATRA shares were sold short, 3.0% of the shares outstanding, down 15.3% from the report before. At the average daily volume of 22,085 shares, buying them all back would take about 13.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 296,651 | 2.96% | -15% | 22,085 | 13.4 |
| Oct 15, 2026 | 350,260 | 3.49% | +9% | 40,263 | 8.7 |
| Sep 30, 2026 | 321,792 | 3.21% | -20% | 39,657 | 8.1 |
| Sep 15, 2026 | 404,270 | 4.03% | -5% | 55,057 | 7.3 |
| Aug 31, 2026 | 427,435 | 4.26% | -10% | 38,619 | 11.1 |
| Aug 14, 2026 | 477,268 | 4.75% | -11% | 51,842 | 9.2 |
| Jul 31, 2026 | 536,897 | 6.57% | -7% | 57,166 | 9.4 |
| Jul 15, 2026 | 577,635 | 7.06% | +60% | 92,530 | 6.2 |
| Jun 30, 2026 | 361,520 | 4.42% | -27% | 91,505 | 4.0 |
| Jun 15, 2026 | 492,405 | 6.02% | +2% | 78,554 | 6.3 |
| May 29, 2026 | 484,391 | 5.92% | -11% | 166,237 | 2.9 |
| May 15, 2026 | 546,470 | 6.68% | +79% | 7.39M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Atara Biotherapeutics company events
Atara Biotherapeutics filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 26, 2026LeadershipAtara Biotherapeutics, Inc. notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026. Filing
- Jun 12, 2026LeadershipThe Board of Directors of Atara Biotherapeutics, Inc. appointed Brian Cherry to serve as a member of the Board as a Class I director, effective June 11, 2026. Filing
- May 7, 2026AnnouncementAtara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” providing an update following the Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter for the EBVALLO™ Biologics License… Filing
- May 1, 2026ListingAtara Biotherapeutics, Inc. received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the Company no longer meets Nasdaq’s $50 million minimum market value for listed securities requirement pursuant to Nasdaq Listing Rule 5450(b)(2)(A)… Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Mar 12, 2026AnnouncementAtara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” announcing that the Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter for the EBVALLO™ Biologics License Application issued… Filing
- Mar 3, 2026AnnouncementAtara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” announcing that Pierre Fabre Pharmaceuticals, Inc. has submitted a request for a Type A meeting with the U.S. Food and Drug Administration to discuss the plan to address the… Filing
- Feb 23, 2026AgreementAtara Biotherapeutics, Inc., entered into an Amendment to the Purchase and Sale Agreement dated as of December 20, 2022 with HCR Molag Fund, L.P. Filing
- Jan 12, 2026AnnouncementBelow, on January 12, 2026, Atara Biotherapeutics, Inc. announced its cash, cash equivalents and short term investments as of December 31, 2025. Filing
- Jan 2, 2026AgreementAtara Biotherapeutics, Inc., entered into the Fourth Amendment to the Amended and Restated Commercialization Agreement dated October 31, 2023 with Pierre Fabre Medicament. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Atara Biotherapeutics financials
Famous investors that hold ATRA
2 of the 50 well-known investors we track reported holding ATRA in their latest 13F filing. The largest position is Steve Cohen's, worth $5.8M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 677,696 | $5.8M | 0.0% | -1% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 43,079 | $366K | 0.0% | +324% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Atara Biotherapeutics, Inc. (ATRA) stock
Who owns the most ATRA stock?
The largest reported owner of Atara Biotherapeutics, Inc. (ATRA) is EcoR1 Capital, LLC, with 19.0% of the company. In total, 35 funds and institutions reported holding ATRA at the end of Q2 2026, together about 55% of the shares. See the largest owners.
Are ATRA insiders buying or selling?
In the last 12 months, ATRA insiders reported 2 open-market purchases worth $5.7M and 18 sales worth $3.9M. The latest trade was on Sep 4, 2026. See every trade.
What is the short interest in ATRA?
As of Oct 30, 2026, 296,651 ATRA shares were sold short, 3.0% of the shares outstanding, down 15.3% from the report before. At the average daily volume of 22,085 shares, buying them all back would take about 13.4 trading days (days to cover). See the history.
Which famous investors hold ATRA?
2 of the 50 well-known investors we track reported ATRA in their latest 13F filing, including Steve Cohen, Ken Griffin. The largest position is worth $5.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.